Quantitative Systematic Strategies LLC purchased a new stake in Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 7,971 shares of the company’s stock, valued at approximately $299,000.
Several other hedge funds have also recently bought and sold shares of the company. BlackRock Inc. raised its stake in Pacira Pharmaceuticals by 122.7% in the first quarter. BlackRock Inc. now owns 2,497 shares of the company’s stock valued at $133,000 after buying an additional 1,376 shares in the last quarter. M&T Bank Corp purchased a new stake in Pacira Pharmaceuticals during the first quarter valued at about $300,000. Parametrica Management Ltd purchased a new stake in Pacira Pharmaceuticals during the second quarter valued at about $338,000. Fox Run Management L.L.C. purchased a new stake in Pacira Pharmaceuticals during the second quarter valued at about $449,000. Finally, Prudential Financial Inc. raised its stake in Pacira Pharmaceuticals by 257.2% in the first quarter. Prudential Financial Inc. now owns 13,376 shares of the company’s stock valued at $709,000 after buying an additional 9,631 shares in the last quarter.
Shares of Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) traded down 0.18% during trading on Friday, reaching $33.19. 536,360 shares of the company were exchanged. The stock’s market capitalization is $1.24 billion. Pacira Pharmaceuticals Inc. has a one year low of $31.08 and a one year high of $80.25. The stock has a 50-day moving average price of $37.73 and a 200-day moving average price of $43.65.
Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its earnings results on Thursday, August 4th. The company reported $0.19 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.03 by $0.16. The business had revenue of $69.60 million for the quarter, compared to analyst estimates of $67.80 million. Pacira Pharmaceuticals had a negative net margin of 4.21% and a positive return on equity of 0.02%. Pacira Pharmaceuticals’s revenue was up 17.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.20 EPS. Analysts forecast that Pacira Pharmaceuticals Inc. will post $0.44 EPS for the current year.
Several analysts recently issued reports on the stock. Brean Capital reiterated a “hold” rating on shares of Pacira Pharmaceuticals in a research report on Friday, August 5th. Wedbush restated an “outperform” rating and issued a $105.00 target price (down previously from $109.00) on shares of Pacira Pharmaceuticals in a research report on Thursday, August 4th. Mizuho restated a “buy” rating on shares of Pacira Pharmaceuticals in a research report on Wednesday, June 22nd. Cowen and Company restated a “hold” rating on shares of Pacira Pharmaceuticals in a research report on Friday. Finally, Zacks Investment Research upgraded shares of Pacira Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $52.00 target price on the stock in a research report on Wednesday, August 10th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $72.83.
In other Pacira Pharmaceuticals news, CEO David M. Stack sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $45.32, for a total value of $679,800.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, President James S. Scibetta sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $45.21, for a total transaction of $1,130,250.00. The disclosure for this sale can be found here. Corporate insiders own 6.90% of the company’s stock.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control.
Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Pharmaceuticals Inc. (NASDAQ:PCRX).
Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.